HOW IT IS THOUGHT TO WORK

TRODELVY IS DESIGNED TO WORK DIFFERENTLY THAN TRADITIONAL CHEMOTHERAPIES

Image showing how TRODELVY® (sacituzumab govitecan-hziy) is thought to work – annotated image
What TRODELVY is made of

TRODELVY is a type of drug called an antibody-drug conjugate, or ADC for short. Unlike traditional chemotherapy, ADCs contain 3 parts: an antibody, an anti-cancer drug, and a linker.

A Antibody

Looks for a specific protein, in this case Trop-2, which is found to be overexpressed in many cancers, including breast cancer

B Anti-cancer drug

Kills cancer cells once they’re found

C Linker

Connects the anti-cancer drug to the antibody

How TRODELVY is thought to attack TNBC tumors

Scientists discovered that patients with triple-negative breast cancer (TNBC) have tumor cells that more often contain the Trop-2 protein. TRODELVY binds to cells with Trop-2.

Information from laboratory studies suggest that this is how TRODELVY works. The clinical benefit of these observations is unknown.

Image showing how TRODELVY® (sacituzumab govitecan-hziy) is thought to work #1
1. Attaches

The antibody in TRODELVY finds and sticks to the Trop-2 protein

Image showing how TRODELVY® (sacituzumab govitecan-hziy) is thought to work #2
2. Penetrates

Once attached, TRODELVY delivers an anti-cancer drug directly into the TNBC cells.

Image showing how TRODELVY® (sacituzumab govitecan-hziy) is thought to work #3
3. Destroys

TRODELVY kills the TNBC cells from within.

Trodelvy is the first and only mTNBC treatment
to target THE Trop-2 PROTEIN